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a b s t r a c t
Maturation of the vaccinia virion is an intricate process that results in the organization of the viroplasm
contained in immature virions into the lateral bodies, core wall and nucleocapsid observed in the mature
particles. It is unclear how this organization takes place and studies with mutants are indispensable in
understanding this process. By characterizing an inducible mutant in the A3L gene, we revealed that A3,
an inner core wall protein, is important for formation of normal immature viruses and also for the
correct localization of L4, a nucleocapsid protein. L4 did not accumulate in the viral factories in the
absence of A3 and was not encapsidated in the particles that do not contain A3. These data strengthen
our previously suggested hypothesis that A3 and L4 interact and that this interaction is critical for proper
formation of the core wall and nucleocapsid.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Vaccinia virus, the best studied member of the Poxviridae family,
encapsidates its dsDNA genome in a complex and unique structure.
The vaccinia virion structure consists of a membrane surrounding a
biconcave core with a lateral body in each concavity of the core (Moss,
2013). The core can be divided into two substructures, an external core
wall and an internal nucleocapsid. The core wall contains two layers:
the outer layer is formed by the proteins A10 (also known as 4a) and
A4, while the inner layer is formed by the protein A3 (also known
as 4b) (Moussatche and Condit, 2014; Ichihashi et al., 1984; Roos et al.,
1996; Pedersen et al., 2000; Wilton et al., 1995). The protein com-
position of the nucleocapsid is not well deﬁned, however it contains
the viral transcription enzymes at a minimum (McFadden et al., 2012;
Peters and Mueller, 1963). The L4 protein may serve as a scaffold for
the nucleocapsid and the viral DNA is probably part of the nucleo-
capsid as well (Jesus et al., 2014). The vaccinia virus core is a dynamic
structure, representing the environment where early viral transcrip-
tion occurs upon entry of vaccinia virus in the host cell.
Because vaccinia encodes all the enzymes required for DNA
replication and transcription, virus replication occurs essentially
independently of the host cell nucleus. All stages of gene expression
(early, intermediate and late) and virus assembly occur in the cell
cytoplasm (Moss, 2013). The assembly of vaccinia virus particles
occurs in areas called viral factories that are cleared of cell organelles
(Condit et al., 2006). Brieﬂy, membrane crescents, the ﬁrst structure
visualized in the cytoplasm, grow to form spherical immature virions
after association with viroplasm. The immature virions encapsidate
one copy of viral DNA and mature to form infectious viruses. The
maturation requires cleavage of several viral proteins. During matu-
ration the virions morph from spherical to the classical brick shape
and the viroplasm mass is organized into the viral core and the
lateral bodies. Even though several players in vaccinia morphogen-
esis have been characterized, the exact process by which these
players orchestrate the arrangement of the viroplasm mass into
lateral bodies, core wall and nucleocapsid is still obscure.
The A3 protein, together with A10 and L4, comprises one of the
major core structural proteins and is one of the key players required
for virus core formation. A3 is expressed during the late phase of
gene expression as a 72.5 kDa precursor and is cleaved during virus
maturation (Katz and Moss, 1970; Ansarah-Sobrinho and Moss,
2004). Several independent studies have suggested that A3 forms
the inner layer of the core wall (Ichihashi et al., 1984; Wilton et al.,
1995; Sarov and Joklik, 1972; Pedersen et al., 2000; Moussatche and
Condit, 2014). In addition, A3 has the ability to bind DNA (Ichihashi
et al., 1984).
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The importance of the A3 protein for the formation of the vaccinia
virus core was revealed during the characterization of the thermo
sensitive mutant Cts8 (Kato et al., 2004). Analysis of Cts8 showed
that, in the presence of a mutated A3, mature viral particles are
misshapen and have a defective virus core, which results in a block in
viral early transcription. With the intention of extending the under-
standing of A3 function, we decided to compare the phenotype of
Cts8, which encapsidates a mutated form of A3, with a mutant that
lacks A3 altogether. For this purpose, we analyzed an inducible
mutant in A3L gene. Analyzing both types of mutants is important for
obtaining a complete understanding of protein function because in
some cases a different phenotype is observed if the protein is absent
from infection compared to an infection in which a mutated form of
the protein is present (Boyd et al., 2010a, 2010b; Szajner
et al., 2003; Mercer and Traktman, 2005).
In this study, we report that in the absence of A3 no infectious
viral particles are produced. Under these conditions, cleavage of
core proteins during maturation is inhibited, and abnormal imma-
ture particles accumulate in the cell cytoplasm. Interestingly, in the
absence of A3, accumulation of the L4 nucleocapsid protein in
the viral factories is decreased and L4 is not present in the viral
particles. This result reinforces the suggestion, raised in our pre-
vious studies, that the A3 inner core wall protein interacts with the
L4 nucleocapsid protein (Jesus et al., 2014).
Results
Construction and characterization of an inducible recombinant virus
in gene A3L
In order to study the function of the vaccinia virus A3 protein, we
constructed an inducible mutant in gene A3L using the E. coli lac
operon system (Zhang and Moss, 1991). The approach chosen is
based on the Lac operon inducible system developed by Alexander
et al. (1992) and Ward et al. (1995) as modiﬁed by Turner and Moyer
(1992) and involves the recombination of a PCR fragment into
the genome of VACVT7lacOI. The PCR fragment contains sequences
homologous to the vaccinia genome ﬂanking a region of the plasmid
pVOTE.2, which contains the T7 polymerase promoter under the
control of the lac operator and the GPT gene under the control of a
vaccinia constitutive promoter as the selective marker. Once recom-
bination occurs, the PCR fragment substitutes the original promoter
of A3L with the T7 RNA polymerase promoter and lac operator
(Fig. 1A). The parental virus (VACVT7LacOI) contains the lac repressor
under the control of a constitutive vaccinia promoter as well as the
T7 RNA polymerase gene under the control of the lac operator and a
late vaccinia promoter.
Initially, we compared viral plaques formed by vA3i in the
absence and presence of IPTG to the viral plaques formed during a
wild type infection in a plaque assay. Monolayers were infected
with serial dilutions of the viruses, incubated at 37 1C in the
absence or presence of IPTG for 7 days and stained with crystal
violet. Fig. 1B shows that vA3i plaques formed in the presence of
inducer are somewhat smaller than wild type plaques. In the
absence of inducer, no viral plaques were visualized.
To analyze virus growth during one replication cycle, cells were
infected with WR or vA3i at an MOI of 10, incubated at 37 1C in the
presence or absence of IPTG and harvested after varying times of
infection (Fig. 1C). In the presence of IPTG vA3i grows slower than
the wild type virus, consistent with the smaller plaque sizes
observed in this condition; however, the mutant reaches wild
type titer levels after 48 h of infection. By contrast vA3i does not
grow in the absence of IPTG. The data from Fig. 1 conﬁrm that vA3i
is dependent on IPTG to produce infectious particles.
Accumulation of A3 during infection
In order to determine if the expression of A3L was repressed in
the absence of IPTG, we infected cells with WR or vA3i at an MOI
of 10 and incubated at 37 1C in the presence or absence of IPTG. At
varying times post-infection, cells were harvested and the samples
analyzed by Western blot. Because A3 is processed during virus
maturation, two bands are observed in the Western blot, corre-
sponding to the uncleaved and cleaved A3. In the presence of IPTG,
A3 accumulates slower than in the wild type infection, with A3
ﬁrst appearing after 12 h versus after 6 h in infections with WR
(Fig. 1D). This slower accumulation of A3 is consistent with the
slower rate of virus growth observed in the one-step growth
experiment. In addition, there is a slight accumulation of A3 even
when IPTG was not added to the cells. This small amount of A3 in
the absence of IPTG is, however, not enough to permit virus
growth (Fig. 1C). Finally, the small amount of A3 present at 48 h
Fig. 1. Initial characterization of vA3i. (A) Illustration of the ﬁnal genome structure
in the region between A3L and A4L genes in vA3i. The viral A3L and A4L genes are
represented by black arrows. pT7 and pE/L represent the bacteriophage T7 and
synthetic vaccinia virus early/late promoters, respectively. GPT¼guanine phos-
phoribosyl transferase. EMC¼the encephalomyocarditis virus independent ribo-
some entry site. SLO¼modiﬁed (stem-loop) lac operator. (B) Viral plaques
phenotype. Cells were infected with WR or vA3i, incubated at 37 1C in the presence
or absence of IPTG and stained with crystal violet after 7 days. (C) One-step growth
curve. Cells were infected with WR or vA3i at an MOI of 10 and incubated at 37 1C
in the presence or absence of IPTG. After varying times of infection, cells were
harvested and the virus titer was determined by plaque assay in the presence of
IPTG. (D) Accumulation of A3 during infection. Cells were infected at an MOI of 10
with WR or vA3i and incubated in the presence or absence of IPTG at 37 1C. At
varying times post-infection, cells were harvested and samples were analyzed by
SDS-PAGE and Western blot with antibodies against A3. The numbers above each
lane indicate hours post-infection.
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during vA3i infection in the absence of IPTG appears largely
uncleaved, indicating that the processing of A3 is inhibited when
compared to wild type and vA3i in the presence of IPTG.
Protein synthesis and processing during vA3i and WR infections
The analysis of protein synthesis provides an overview of virus
gene expression. In order to determine if any stage of gene
expression was blocked in infections done with the mutant under
non-permissive conditions, we infected cell monolayers with WR or
vA3i at an MOI of 10 and incubated the cells in the presence or
absence of IPTG. At varying times post infection, we added 35S-
methionine to the cells. After 30 min, cells were harvested and the
samples analyzed by SDS-PAGE and autoradiography. In Fig. 2, we
observe the appearance of viral early proteins at 3 h in wild type
infections. At 6 h, synthesis of late proteins starts and continues
through 24 h of infection. In addition to appearance of viral proteins,
the background of cellular proteins decreases with time, a conse-
quence of the shut off of host protein synthesis by the virus. The
only striking difference between wild type infections and infections
done in the absence of IPTG is observed at the region between the
molecular masses of 75 and 50 kDa. In the wild type infection, the
prominent band appearing at approximately 90 kDa corresponds to
the precursor form of A10. Processed A10, the precursor form of
A3, and processed A3 all comigrate as a prominent band at appro-
ximately 65 kDa. vA3i infections appear essentially identical to the
wild type infection with the exception that one additional band
corresponding to T7 RNA polymerase appears at approximately
100 kDa. During infection with vA3i in the absence of IPTG, the
A10 precursor is still present, T7 RNA polymerase is absent, and the
band appearing at 65 kDa is decreased in intensity, consistent with
repression of both A3 synthesis and A10 processing. We assume that
the remaining intensity at 65 kDa apparent in vA3i infections in the
absence of ITPG represents an additional late viral protein that
normally comigrates with pA3, A3 and A10. From this experiment,
we conclude that in the absence of IPTG there is no inhibition of any
of the phases of gene expression.
Proteolytic processing is a crucial step for vaccinia virion
maturation. To test whether the absence of A3 indeed results in
blockage of protein cleavage, we performed both a pulse chase
assay and Western blot analysis. For the pulse chase analysis, we
infected cells with WR or vA3i at an MOI of 10 in the presence or
absence of IPTG for 8 h, at which time 35S-methionine was added to
the cells for 30 min. Some of the cells were harvested immediately
after the 35S-methionine pulse while others were incubated in the
absence of radiolabel and in the presence or absence of IPTG and
harvested at varying times. Samples were analyzed by SDS-PAGE
and autoradiography (Fig. 3A). For the Western blot analysis, we
infected cells with WR or vA3i at an MOI of 10 in the presence or
absence of IPTG, harvested infections at varying times post infec-
tion, and probed Western blots with antibodies against A10 and L4,
two prominent processed structural proteins (Fig. 3B). Although
some quantitative and kinetic differences are apparent, qualitatively
all three structural proteins, A10, A3 and L4 are processed in both
wild type and vA3i infections (Figs. 1D and 3). By contrast, in vA3i
infections done in the absence of IPTG, A3 is absent and processing
Fig. 2. Analysis of protein synthesis. Cells were infected with WR or vA3i at an MOI of 10 and incubated in the presence or absence of IPTG at 37 1C. At varying times post-
infection, infected cells were incubated with medium containing 35S-methionine. After 30 min, cells were harvested in sample buffer and analyzed by SDS-PAGE and
autoradiography. The numbers on the top indicate hours post-infection. The star on the left marks the unidentiﬁed band observed during infections with vA3i in the absence
of IPTG. The molecular weight in kDa is on the left.
Fig. 3. Analysis of protein processing. (A) Cells were infected at an MOI of 10 with
WR or vA3i and incubated in the presence or absence of IPTG at 37 1C. After 8 h of
infection, cells were incubated with 35S-methionine for 30 min. Some cells were
harvested after the pulse (P) while others were incubated in the presence or
absence of IPTG for varying times (chase). The numbers on the top represent hours
after the pulse. The molecular weight in kDa is on the right. (B) Cells were infected
as described previously and harvested in sample buffer. Samples were analyzed by
SDS-PAGE and Western blot using antibodies against L4 or A10 proteins. The
numbers on the top represent hours of infection.
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of both A10 and L4 is signiﬁcantly reduced (Figs. 1D and 3). Taken
together, these results show that the proteolytic processing is
reduced in the absence of A3.
Virus assembly in the absence of A3
The inhibition of proteolytic processing suggests a block in virus
maturation in the absence of A3. To test this hypothesis, we analyzed
virus assembly after 24 h of infection by transmission electron micro-
scopy. Fig. 4A and B shows the normal immature and mature viruses
produced in a wild type infection, respectively. A similar phenotype is
observed with vA3i in the presence of IPTG (Fig. 4C and D). In the
absence of inducer, the majority of the viral particles observed in the
cell cytoplasm are immature virions (Fig. 4E), with a small percentage
of abnormal, electron dense viral particles (Fig. 4F). Most of the IVs
are half empty, with the viroplasm localized to the periphery of the
particle. However, nucleoids are observed in several immature
particles, suggesting that DNA is packaged. These data are consis-
tent with the inhibition in protein cleavage observed in Fig. 3 and
demonstrate that A3 is required for normal immature virions
formation.
Characterization of viral particles formed in the absence of A3
Given the difﬁculty in purifying immature viruses, we used
immunogold labeling to analyze the protein content of viral particles
formed in the absence of IPTG. Cells infected at an MOI of 10 for 24 h
with WR or vA3i were processed for immunoelectron microscopy.
We then probed the ultrathin sections with antibodies against
several structural viral proteins. Because A3L gene is expressed
in low amounts even in the absence of IPTG and a few particles
produced under these conditions appear to be more advanced in the
Fig. 4. Analysis of morphogenesis. Cells infected with WR or vA3i at an MOI of 10 were processed for electron microscopy after 24 h of infection. (A) and (B) WR; (C) and
(D) vA3i in the presence of IPTG; (E) and (F) vA3i in the absence of IPTG. Normal immature virions are represented in (A) and (C). Normal mature virions are represented in
(B) and (D). (E) and (F) represents abnormal IVs and MVs produced under non-permissive conditions. Arrows point to half-empty immature virions. Bars¼500 nm.
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path to viral maturation than IVs, we wanted to determine whether
these electron dense viral particles corresponded to virions that
contained small amounts of A3. However this is not the case as we
observed only background labeling of both IVs and abnormal viral
particles in vA3i infections done in the absence of IPTG (data not
shown). Control experiments revealed that, as expected, A3 was
Fig. 5. Immunogold labeling against structural proteins. Cells infected with WR or vA3i at an MOI of 10 were processed for electron microscopy after 24 h of infection.
Ultrathin sections were probed with anti-D13 (10 nm gold) and anti-A27 (15 nm gold) (A) to (C) or with anti-A10 (D) to (I). (A), (D) and (E) WR; (B), (F) and (G) vA3i in the
presence of IPTG; (C), (H) and (I) vA3i in the absence of IPTG. Bars¼250 nm.
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present in both IVs and MVs of particles produced in the presence of
A3 (data not shown).
We hypothesize that the electron-dense particles formed in
vA3i infections in the absence of inducer are abnormal mature
particles. To test this hypothesis, we probed sections with anti-D13
(which labels only IVs) and anti-A27 (which labels only MVs).
Fig. 5A and B shows the presence of A27 and D13 in normal MVs
and IVs, respectively. We conclude that the abnormal electron-
dense particles are indeed abnormal mature particles, as they
contain A27, but not D13, while the opposite is observed for the
IVs (Fig. 5C).
Prior studies suggest that A3 is a component of the inner layer
of the core wall, while A10 forms the external layer of the core wall
in a complex with A4 (Moussatche and Condit, 2014; Ichihashi
et al., 1984; Risco et al., 1999). Given these observations, we were
interested in analyzing whether A10 is contained in viral particles
formed in the absence of A3. Control immunogold labeling with
anti-A10 antibody demonstrates that A10 is present during wild
type infections in both immature (Fig. 5D) and mature (Fig. 5E)
particles, and during vA3i infections done in the presence of IPTG
in both immature (Fig. 5F) and mature (Fig. 5G) particles. Anti-A10
labeling was also observed in experimental vA3i infections done in
the absence of inducer in both immature (Fig. 5H) and aberrant
mature (Fig. 5I) particles. Therefore, A10 is encapsidated in the
virus particles irrespective of the presence of A3.
Another abundant internal core structural protein is L4, which we
have proposed is a major structural component of the nucleocapsid
(Jesus et al., 2014). To test the dependence of L4 packaging on A3, we
conducted immunogold labeling experiments simultaneously prob-
ing for L4 and, as a control, A14, a component of the viral membrane.
In wild type infections both immature (Fig. 6A) and mature particles
(Fig. 6B) label with both anti A14 and anti L4. In vA3i infections done
Fig. 6. Immunogold labeling against L4. Cells infected with WR or vA3i at an MOI of 10 were processed for electron microscopy after 24 h of infection. Ultrathin sections were
probed with anti-L4 (10 nm gold) and anti-A14 (15 nm gold). (A) and (B) WR; (C) and (D) vA3i in the presence of IPTG; (E) and (F) vA3i in the absence of IPTG. Bars¼250 nm.
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in the presence of IPTG both immature (Fig. 6C) and mature (Fig. 6D)
viral particles label with both anti A14 and anti L4. However, in vA3i
infections done in the absence of IPTG, the labeling for L4 is noticeably
decreased in both immature (Fig. 6E) and aberrant mature (Fig. 6F)
particles, while labeling with anti A14 remains equivalent to control
infections. The number of viral particles labeled for L4 containing at
least one gold particle was quantiﬁed for all conditions and the results
are shown in Table 1. Statistical analysis shows that the difference in
L4 labeling between IVs produced during vA3i infection in the absence
and presence of inducer is not signiﬁcant (p¼0.07). However, when
we compared IVs from vA3i in the absence of IPTG andWR infections,
the difference in labeling against L4 was signiﬁcant (p¼6.5105).
Statistical analysis of MV labeling demonstrated a signiﬁcant difference
when we compared vA3i in the presence and absence of inducer
(p¼0.04) while the difference between vA3i in the absence of IPTG
and wild type was not signiﬁcant (p¼0.06). However, we are
conﬁdent that L4 is not efﬁciently encapsidated in the absence of A3
because when the statistical analysis was done considering both IVs
and MVs together, there was signiﬁcant difference between both
comparisons, namely vA3i in the absence versus presence of IPTG
(p¼0.004) as well as vA3i in the absence of IPTG versus wild type
(p¼0.004). Moreover, analyzing the number of gold particles per
virion, we observe that viral particles containing A3 have a higher
density of labeling, up to 12 gold spheres per particle, compared to
viral particles formed in the absence of A3 (maximum 6 gold spheres
per viral particle) (Fig. 7). Additionally, the viral particles produced in
the absence of A3 have a greater tendency to label with only one gold
sphere compared viral particles that contain A3. These results derive
from three independent immunogold labeling experiments against L4
protein. Other viral proteins were analyzed as well (A4, F17, D1),
however only L4 presented differential labeling when A3 was absent
from infection (data not shown).
Analysis of L4 localization in infected cells
Because we observed reduced encapsidation of L4 when A3 is
absent from infections, it was of interest to analyze the behavior of
L4 in infected cells. For this purpose, cells were infected at an MOI
of 2 with either wild type or vA3i in the absence or presence of IPTG
and analyzed at 9 h post infection by immunoﬂuorescence confocal
microscopy. Results in Fig. 8 show that A3 localizes to the viral
factories in wild type infections as well as in infections with vA3i in
the presence of inducer. In the absence of inducer, we observed a small
amount of A3 in viral factories, consistent with the Western blot of
Fig. 1D showing limited accumulation of A3 even in the absence of
IPTG. In contrast to A3, L4 shows diffuse staining throughout the cell
cytoplasm under all conditions tested. However, in infections with
wild type virus or vA3i in the presence of inducer, L4 also accumulates
in the viral factories. This accumulation is noticeably decreased when
A3 is not present during infection. It is important to note that the low
MOI used allowed us to analyze uninfected and infected cells in the
same sample. Uninfected cells did not present the diffuse staining
observed with the antibody against L4. Therefore the diffuse staining
was not due to background, but represents the actual distribution of
L4 in the cytoplasm. We also analyzed the localization of A10 as a
control for a viral structural protein that is encapsidated in the viral
particles regardless of the presence of A3. We observed decreased
labeling of A10 in viral factories during vA3i infections done in the
absence of inducer when compared to the viral factories that contain
A3. However, A10 still accumulates in the factories and is encapsidated
in viral particles that lack A3. The analysis of D13 and A14 localization
showed that both proteins are present in the virus factories even
when A3 is absent from infection (Fig. 8). These results show that
the presence of A3 in the viral factories is important for proper L4
localization.
Discussion
Vaccinia virus morphogenesis is an intricate process that gen-
erates virions of distinct morphology. Studying function and loca-
lization of each individual protein in the virion is indispensable for
understanding in detail how the viroplasm contained in immature
particles is reorganized into the virus core of mature particles. A3 is
one of the most abundant proteins in the virion and previous studies
Table 1
Quantiﬁcation of L4 in IV and MVa.
% Of IV with gold
(number of total
IVs)
% Of MV with gold
(number of total
MVs)
% Of total particles with
gold (number of total
particles)
vA3i
()
IPTG
39 (665) 29 (146) 37 (811)
vA3i
(þ)
IPTG
67 (243) 84 (203) 75 (446)
WR 98 (79) 75 (459) 78 (538)
a Several random ﬁelds of the electron micrographs were analyzed and the
number of viral particles with and without gold nanoparticles was quantiﬁed. The
numbers represent cumulative data from three independent experiments. Statis-
tical signiﬁcance was calculated using the t-test (see text).
Fig. 7. Quantiﬁcation of L4 labeling. Several electron micrographs were analyzed and the number of gold nanoparticles labeling individual viral particles was quantiﬁed and
plotted in a histogram.
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Fig. 8. Analysis of viral proteins localization. Cells were infected at an MOI of 2 for 9 h with WR or vA3i in the absence or presence of IPTG. Infected cells were prepared for
analysis by confocal microscopy, using antibodies against several viral proteins. The images represent the collapsed Z-stack.
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demonstrated its localization to the inner layer of the virus core wall
(Moussatche and Condit, 2014; Ichihashi et al., 1984). In order to
understand the importance of A3 during vaccinia virion assembly, we
analyzed infections in which A3 was absent using an inducible
mutant. In addition, we were interested in assessing the possible
interaction between A3 and L4. A possible association between A3
and L4 was suggested in a previous study from our group showing
that mutants in L4, which is likely a nucleocapsid structural protein,
affect both nucleocapsid and core wall formation (Jesus et al., 2014).
In the current study, we showed that the phenotype of the
inducible mutant is distinct from the gene A3L thermosensitive virus
mutant Cts8 (Kato et al., 2004). In vA3i infections in the absence
of IPTG, the assembly pathway is blocked at an earlier stage than
observed with Cts8 infections done under non-permissive condi-
tions. Cts8 mutant infections result in formation of normal IVs and
accumulation of numerous aberrant MVs with malformed cores. vA3i
mutant infections result in the accumulation of aberrant IVs in the
cytoplasm. A minority of these IVs starts the process of maturation,
but the process is not completed and aberrant mature particles are
formed. The difference in phenotype probably results from the fact
that Cts8 mutant infections produce normal amounts of mutant A3
protein which is encapsidated into aberrant virions (Kato et al.,
2004), whereas vA3i mutant infections lack A3 altogether.
It is unclear why in vA3i mutant infections some IVs are able to
start to mature beyond the IV stage to become aberrant MVs.
Attempts to determine if the aberrant mature particles contained
limited amounts of A3, derived from leakiness of the mutant,
showed no difference in labeling of the two types of viral particles,
IVs or aberrant MVs; both types of particles labeled weakly for A3,
as expected (data not shown). We suggest that if there is a
difference in the amount of A3 between these viral particles, this
difference may be below the level of sensitivity of the immunogold
labeling technique.
Vaccinia late proteins are translated in viral factories, so the fact
that L4 accumulation is decreased in viral factories when A3 is absent
suggests that L4 is leaving the viral factories under these conditions
(Katsafanas and Moss, 2007; Rozelle et al., 2014). Because L4 binds to
microtubules and microtubules are required for exit of MVs from
viral factories, we suggest that the L4-microtubule interaction is
responsible for L4 egress from viral factories in the absence of A3
(Katsafanas and Moss, 2007; Mallardo et al., 2001; Ploubidou et al.,
2000). We also observed a decrease in the amount of A10 in the
factories when A3 is absent. A10, like L4, binds to microtubules
(Ploubidou et al., 2000). However, the decrease in A10 accumulation
was not as striking as observed for L4 and this might be explained by
the retention of A10 in the factories by A4, as A10 and A4 form a
complex at the beginning of morphogenesis (Risco et al., 1999). The
presence of A3 in viral factories in the absence of A10 has not been
analyzed. Nevertheless, the accumulation of A3 during infection is
decreased in the absence of A10 (Heljasvaara et al., 2001). Together
these ﬁndings suggest a complex interaction among the major core
proteins, A3, L4, A10 and A4, during virion assembly.
By comparing the phenotype of vA3i with an inducible mutant in
the A10L gene (Heljasvaara et al., 2001), we suggest that the retention
of L4 in the viral factories and L4 encapsidation depend on the
presence of both core wall proteins. In the experiments reported here,
we demonstrate that in the absence of A3, L4 fails to accumulate in the
viral factories and is not encapsidated in the virions, consistent with
our previously proposed interaction between core wall (A3 protein)
and nucleocapsid (L4 protein) (Jesus et al., 2014). Similarly, in the
absence of A10, L4 is not encapsidated in the viral particles
(Heljasvaara et al., 2001). It is not known whether there is a change
in L4 intracellular localization in the absence of A10. Given these
results, we suggest that the core wall proteins are important for the
encapsidation of L4. Provocatively, a similar scenario is observed
during the assembly of African swine Fever Virus (ASFV). In this case,
two viral proteins interact to form the core shell (the core shell would
be the equivalent to the core wall of vaccinia) (Andres et al., 2002a). If
the core shell is not formed because of the absence of one of the core
shell proteins, the nucleoproteins are not encapsidated in the virions
(Andres et al., 2002b). These observations suggest a connection
between the core wall proteins and the nucleocapsid scaffold protein.
The absence of A3 or A10 arrests virus assembly at an earlier stage
than does the absence of L4. In the absence of either A3 or A10,
morphogenesis does not progress beyond the IV stage, whereas in
the case of L4 mutants, the assembly proceeds beyond protein
cleavage and aberrant mature virus particles are produced (Jesus
et al., 2014; Wilcock and Smith, 1994). Thus it is tempting to
speculate that the core wall precedes the nucleocapsid formation. It
is possible that the viral protease I7 may only function if the core wall
proteins are encapsidated, while L4 seems to be dispensable for
protease function. In ASFV, the protease is localized in the core shell
(Andres et al., 2001). It would be interesting to determine whether
the vaccinia protease is also attached to the core wall.
Our ﬁndings reinforce the hypothesis that there is an associa-
tion between core wall and nucleocapsid structure, more speciﬁ-
cally, A3 and L4 proteins and that core wall assembly precedes
nucleocapsid assembly. Lastly, the work emphasizes that studying
different classes of mutants, thermosensitive and inducible, can
provide novel insights into the vaccinia virus replicative cycle.
Material and methods
Cells and viruses
Viruses were grown in BSC-40 cells and mutant selectionwas done
in CV-1 cells, both African green monkey cell lines. BSC-40 cells were
cultured in Dulbecco’s Modiﬁed Eagle’s medium (Life Technologies—
cat. 12100-061) containing 10% fetal bovine serum, 0.12mg/mL
penicillin (Sigma), 0.2 mg/mL streptomycin (Sigma) and 250 μg/mL
fungizone (Sigma). CV-1 cells were cultured in Minimum Essential
media (Life Technologies—cat. 6100-087) supplemented with 5%
fetal bovine serum, 100 units/mL penicillin, 0.1 mg/mL streptomycin,
292 mg/mL glutamine, 1 mM sodium pyruvate and non-essential
amino acids. Wild-type vaccinia virus strain WR and VACVT7LacOI
have been described (Kato et al., 2004; Condit and Motyczka, 1981;
Alexander et al., 1992).
Generation of vA3i
An inducible mutant in the A3L gene (vA3i) was constructed
based on methods developed previously (Turner and Moyer, 1992).
Brieﬂy, two DNA fragments containing the 50 portion of the A3L gene
or the 30 portion of the A4L gene were PCR ampliﬁed using speciﬁc
primers that contained overhang sequences to the plasmid pVOTE.2
(Ward et al., 1995). A third DNA fragment comprising the region of
pVOTE.2 containing the guanine-hypoxanthine phosphoribosyl-
transferase (GPT) gene, the lac operator and the T7 RNA polymerase
promoter sequences was ampliﬁed by PCR using primers containing
overhang sequences to vaccinia genes A3L and A4L. The three
amplicons were joined and ampliﬁed in a PCR containing primers
speciﬁc for sequences of A3L and A4L. The resulting PCR amplicon
contained the A3L and A4L regions ﬂanking the T7 promoter and lac
operator plus an adjacent GPT cassette under the control of vaccinia
early/late promoter P7.5. The sequence of this amplicon was
conﬁrmed by Sanger sequencing. The fragment was recombined
into VACVT7LacOI at the site between A3L and A4L, substituting
the natural promoter of A3L by the T7 polymerase promoter and
the downstream lac operator (Alexander et al., 1992) (Fig. 1A).
VACVT7LacOI expresses the Escherichia coli lac repressor constitu-
tively under control of a vaccinia virus promoter, and also expresses
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bacteriophage T7 RNA polymerase conditionally under control of a
vaccinia virus promoter and a lac operator. Selection for the mutant
was done in the presence of mycophenolic acid and isopropyl-β-D-
thiogalactopyranoside (IPTG). Viral plaques grown in the presence of
IPTG and mycophenolic acid were selected and screened for IPTG
dependence in the absence of mycophenolic acid.
Based on an IPTG curve analysis, where BSC-40 cells were
infected at an MOI of 10 for 24 h, the IPTG concentration chosen
was 200 mg/mL. This concentration provided mutant virus growth
comparable to the wild type virus.
Plaque assay
Ten-fold dilutions of the virus were used to infect BSC-40 cell
monolayers. After 1 h of adsorption, the inoculum was removed
and medium supplemented with 1% methylcellulose and 200 mM
IPTG was added. Cells were incubated for 3 or 7 days at 37 1C and
stained with crystal violet.
One-step growth
BSC-40 cells were infected with WR or vA3i at an MOI of 10. After
30 min adsorption, inoculumwas removed and drug free medium or
medium containing 200 mM IPTG was added to the cells. Infected
cells were incubated at 37 1C and harvested at varying times post
infection. Virus titer was determined by plaque assay in the presence
of IPTG.
Western blot analysis
BSC-40 cells were infected at an MOI of 10 with WR or vA3i and
incubated at 37 1C in the absence or presence of IPTG. Infected
cells were harvested at different times post-infection in sample
buffer (50 mM Tris–HCl, pH 6.8; 1% SDS; 10% glycerol; 140 mM
2-mercaptoethanol; 0.1% bromophenol blue). Western blots were
prepared and analyzed as described previously (Kato et al., 2007).
The dilutions and sources of the antibodies used were: anti-L4
(1:50,000) rabbit serum was supplied by Dr. Paula Traktman; anti-
A3 (1:20,000) and anti-A10 (1:20,000) rabbit sera were supplied
by Dr. Bernard Moss. Secondary anti-rabbit antibody was pur-
chased from Santa Cruz Biotechnologies Inc.
Protein pulse-labeling and pulse chase
Cells were infected at an MOI of 10 with WR or vA3i and
incubated at 37 1C in the presence or absence of IPTG. At each time
point, cells were labeled with culture mediumwithout methionine
containing 20 mCi/mL of [35S]methionine (Perkin Elmer). After
30 min incubation at 37 1C, the media was removed and the cells
were harvested in sample buffer. Proteins were analyzed by SDS-
PAGE followed by autoradiography (Condit and Motyczka, 1981).
For pulse-chase experiments, infected cells were pulse-labeled
after 8 h of infection with 10 mCi/mL of [35S]methionine (Perkin
Elmer) for 30 min. Some cells were harvested in sample buffer
immediately after the pulse. For the remaining cells, the label was
washed out and the cells were incubated at 37 1C for varying times
in the presence or absence of IPTG and absence of [35S]methionine.
Proteins were analyzed by SDS-PAGE followed by autoradiography.
Electron microscopy—Conventional sample ﬁxation for ultrastructure
BSC-40 cells were infected with either vaccinia WR or vA3i at
an MOI of 10 and incubated at 37 1C for 24 h in the presence or
absence of IPTG. Infected cells were ﬁxed with 2% glutaraldehyde
in cacodylate buffer (0.1 M sodium cacodylate, 2 mM MgCl2, 1 mM
CaCl2, 43 mM NaCl; pH 7.2) and post-ﬁxed with 1% osmium
tetroxide in water. After dehydration with increasing concentra-
tions of ethanol, samples were embedded in Spur’s resin. Sections
of 70–80 nm thickness were post-stained with 2% uranyl acetate
and lead citrate and visualized in a H-7000 transmission electron
microscope (TEM) (Hitachi High Technologies America, Inc.
Schaumburg, IL) operated at 100 kV. Digital images were acquired
with a Veleta camera and iTEM software (Olympus Soft-Imaging
Solutions Corp, Lakewood, CO). The electron microscopy was done
with assistance of the University of Florida ICBR Electron Micro-
scopy Core Laboratory.
Electron microscopy for immunogold labeling—High pressure
freezing/freeze substitution
BSC-40 cells in 100 mm dishes were infected at an MOI of 10
with WR or vA3i and incubated at 37 1C in the presence or absence
of IPTG. At 24 h post infection, cells were harvested and incubated
with cacodylate buffer containing 4% paraformaldehyde and 1%
glutaraldehyde for 30 min on ice. Fixed cells were pelleted by gentle
centrifugation, washed twice with cacodylate buffer and resus-
pended in 25 mL of cryoprotectant (20% [w/v] dextran 39,000 wt,
prepared in serum free medium). The dextran protected cell
suspension was loaded into a 6 mm aluminum Type A planchette
(Leica Microsystems, Buffalo Groove, IL) that was capped using the
ﬂat side of a 6 mm aluminum Type B planchette. This assembly was
loaded into a holder and immediately frozen using a high pressure
freezing system (HPM 100, Leica Microsystems, Buffalo Grove, IL).
After freezing, cells-planchettes were kept under liquid nitrogen
and transferred to a vial containing 0.1% glutaraldehyde and 0.25%
uranyl acetate in acetone. The vials containing the cells-planchettes
were transferred to the freeze substitution unit (EM AFSII, Leica
Microsystems, Buffalo Grove, IL). Freeze substitution was performed
with the following program: 90 1C for 12 to 48 h followed by
slow warming up from 90 1C to 70 1C for 16 h, from 70 1C to
45 1C for 12 h, from 45 1C to 20 1C for 2 h, from 20 1C to
4 1C for 2 h. Cells were removed from the planchettes and washed
three times with acetone and inﬁltrated with Lowicryl HM20 resin.
Samples were polymerized with 100% Lowicryl at 20 1C with UV
light for 2 days. Ultrathin sections (70–80 nm) were collected on
nickel grids and immunolabeled as described previously (Castro
et al., 2003). The dilutions and sources of the antibodies used were:
anti-L4 (1:100) rabbit serum was supplied by Dr. Paula Traktman;
anti-A3 (1:100) and anti-D13 (1:1000) rabbit sera were supplied
by Dr. Bernard Moss; anti-A14 (1:50) mouse serumwas supplied by
Dr. Yan Xiang; anti-A27 (1:100) mouse serum was supplied by
Dr. David Ulaeto; secondary antibodies anti-rabbit and anti-mouse
(1:50) were purchased from BBI Solutions (Cardiff, CF). Ultrathin
sections (70–80 nm) were post-stained with 2% uranyl acetate and
lead citrate and examined with an H-7000 TEM and images
processed as described above.
Confocal microscopy
BSC-40 cell monolayers were grown in 35 mm glass bottom
dishes (MatTek corp, part P35G-1.5–14-C) and infected at an MOI
of 2. After 30 min adsorption, inoculum was removed and medium
with or without IPTG was added to the cells. After 9 h of incubation
at 37 1C, infected cells were processed for confocal microscopy. All
the steps were done at room temperature. Cells were ﬁxed with 4%
paraformaldehyde in PBS (0.17 M NaCl, 3.3 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4; pH 7.2). After 10 min, the ﬁxative was quenched for
5 min with 20 mM glycine in PBS. Cells were permeabilized with
0.2% Triton X-100 in PBS for 10 min, blocked with PBS containing 10%
fetal bovine serum (FBS) for 10 min and incubated with primary
antibody for 60 min followed by incubation with secondary antibody
for 30 min. The antibodies were diluted in PBS containing 0.1% Triton
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X-100 and 10% FBS. The sources and dilutions of the antibodies were:
anti-A3 (1:250) and anti-D13 (1:500) rabbit sera were supplied by
Dr. Bernard Moss; anti-L4 (1:250) mouse monoclonal antibody was
from our own collection; anti-A10 (1:250) and anti-A14 (1: 250)
mouse monoclonal antibodies were supplied by Dr. Yan Xiang.
Secondary antibodies anti-rabbit and anti-mouse Alexa Fluor 594
or Alexa Fluor 488 (100X diluted) were purchased from Invitrogen
(Carlsbad, CA). Following incubation with antibodies, cells were
stained with DAPI (0.5 mg/mL) (Invitrogen) for 15 min and mounted
on coverslips. Samples were visualized with a LEICA TCS SP2 AOBS
Spectral Confocal (Leica Microsystems Inc., Buffalo Grove, IL).
L4 monoclonal antibody production
The L4 coding sequence was PCR ampliﬁed from WR genomic
DNA and cloned into the Champion pET Directional TOPO expression
vector, containing a His-tag, according to the manufacturer’s instruc-
tions and transformed into E. coli BL21 star DE3 (Life technologies).
Bacteria were grown to A600 density of 0.5–0.6 OD units, the
expression of the foreign protein was then induced with 1 mM IPTG
and the cells were allowed to grow for an additional 4–6 h. The cells
were harvested by centrifugation at 9000 rpm (Sorvall, SS34 rotor)
for 5 min and the pellets were stored at 20 1C.
For protein puriﬁcation, lysates were prepared by resuspending
each pellet in 25 mL of lysis buffer (25 mM Tris–HCl, pH 8, 10%
glycerol, 400 mM NaCl). Lysozyme (50 mg/mL) and NP40 (0.5%) were
then added in order to rupture the cell membranes. The lysates were
incubated on ice for 30 min to allow for complete cell lysis. The
viscous lysates were sonicated for 10 cycles (15 s on; 45 s off; on ice)
to shear DNA and decrease viscosity. The sonicated lysates were then
centrifuged at 18,000g for 30 min at 4 1C and ﬁltered through a
0.22 mm ﬁlter to clarify the lysate. The lysate was applied to a nickel-
afﬁnity column in lysis buffer containing 20 mM Imidazole to allow
for selective binding of the histidine tagged viral proteins present in
the E. coli lysate. The bound proteins were washed with 10 column
volumes (CVs) of lysis buffer containing 20 mM imidazole. Non-
speciﬁcally bound E. coli proteins were subsequently washed off the
column using 10 CVs of lysis buffer containing 150 mM Imidazole.
The puriﬁed his-tagged vaccinia viral L4 protein was eluted in 10–20
CVs of lysis buffer containing 500 mM Imidazole. One milliliter
fractions were collected at various steps of the puriﬁcation and peak
fractions were fractionated on SDS-PAGE and analyzed for the
presence of the target protein by Coomassie staining or immunoblot
analysis using an anti-his antibody and/or a polyclonal antibody
against the L4.
Puriﬁed his tagged L4 protein was submitted to the University of
Florida Hybridoma core for construction of hybridomas. Supernatants
from fusions were screened initially by ELISA against puriﬁed L4
antigen. Positive clones were screened further by Western blot
against puriﬁed WR virions and lysates of WR infected cells, and
by immunoﬂuorescence microscopy against WR infected cells.
A hybridoma was chosen that detected 29 kDa and 25 kD proteins
corresponding to the precursor and processed forms of L4 inWestern
blots and gave a positive signal by immunoﬂuorescence (data not
shown).
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